Associate Lecturer in Medicine
Departments and Institutes
My research focuses on vascular function and inflammation, NO bioavailability and vascular-ventricular interactions. I have a keen interest in identifying novel agents that may improve vascular health, as measured in vivo, in human models of health and disease.
We use well-described models to characterise this in our Department as well as more experimental approaches to stratify patients. These include forearm plethysmography, flow mediated dilatation and arterial stiffness as well as a range of haemodynamic and circulatory measurements. These biomarkers enable us to understand the mechanisms underlying the improvement or deterioration in vascular health in vivo from an NO bioavailability viewpoint, provide proof of concept of human physiology and pathophysiology and also help interrogate the role of various peptides and hormones in the regulation of vascular tone. The strength of these unique types of clinical physiological studies lies in their direct relevance to human biology, occasionally confirming pre-clinical models, but simultaneously providing relevance to human pathophysiology.
We are also interested in developing more novel approaches to understanding vascular pathophysiology using non-invasive imaging and bespoke technologies to understand angiogenesis. These techniques may be applied to human physiological studies and clinical trials of investigational medicinal products. This enables the translation of pre-clinical models of novel therapeutic agents into niche products differentiating an investigational medicinal product from existing therapies, or providing proof of mechanism in order to progress such a product through the stages of clinical drug development. For example, building on some seminal work performed by local collaborators, we have used FDG PET-CT in a novel experimental medicine study to understand the effects of a new therapeutic agent in altering the biology of atherosclerosis. We have applied similar techniques to assess existing therapies for patients with chronic inflammatory conditions, to understand if they possess off-target pharmacology which may improve outcomes as an inadvertent benefit of therapy. Along similar lines, we are aiming to understand how new drugs may disrupt vascular networks in the microcirculatory environment by examining the effects of such therapies on conjunctival vessels in collaboration with Dr Paul Meyer in the Department of Ophthalmology.
atherosclerosis ; clinical trials ; Apelin ; imaging ; angiogenesis ; arterial stiffness
Collaborators outside this directory
- Professor Peter Weissberg - https://www.bhf.org.uk/about-us/who-we-are/our-directors
- Professor Duncan Jodrell - http://www.oncology.cam.ac.uk/research/groupleaders/jodrell.html
Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Brame AL, Maguire JJ, Yang P, Dyson A, Torella R, Cheriyan J, Singer M, Glen RC, Wilkinson IB, Davenport AP. Hypertension. 2015 Apr;65(4):834-40.
The role of epoxyeicosatrienoic acids in the cardiovascular system. Yang L, Mäki-Petäjä K, Cheriyan J, McEniery C, Wilkinson IB. Br J Clin Pharmacol. 2015 Jul;80(1):28-44.
Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial. Gajendragadkar PR, Hubsch A, Mäki-Petäjä KM, Serg M, Wilkinson IB, Cheriyan J. PLoS One. 2014 Jun 9;9(6):e99070.
Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease. Fisk M, Gajendragadkar PR, Mäki-Petäjä KM, Wilkinson IB, Cheriyan J. Am J Cardiovasc Drugs. 2014 Jun;14(3):155-65.
Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers. Barbour AM, Sarov-Blat L, Cai G, Fossler MJ, Sprecher DL, Graggaber J, McGeoch AT, Maison J, Cheriyan J. Br J Clin Pharmacol. 2013 Jul;76(1):99-106.
Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Mäki-Petäjä KM, Elkhawad M, Cheriyan J, Joshi FR, Ostör AJ, Hall FC, Rudd JH, Wilkinson IB. Circulation. 2012 Nov 20;126(21):2473-80.
Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure. Pucci G, Cheriyan J, Hubsch A, Hickson SS, Gajendragadkar PR, Watson T, O'Sullivan M, Woodcock-Smith J, Schillaci G, Wilkinson IB, McEniery CM. J Hypertens. 2013 Jan;31(1):77-85.
Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. Elkhawad M, Rudd JH, Sarov-Blat L, Cai G, Wells R, Davies LC, Collier DJ, Marber MS, Choudhury RP, Fayad ZA, Tawakol A, Gleeson FV, Lepore JJ, Davis B, Willette RN, Wilkinson IB, Sprecher DL, Cheriyan J.JACC Cardiovasc Imaging. 2012 Sep;5(9):911-22.
Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Cheriyan J, Webb AJ, Sarov-Blat L, Elkhawad M, Wallace SM, Mäki-Petäjä KM, Collier DJ, Morgan J, Fang Z, Willette RN, Lepore JJ, Cockcroft JR, Sprecher DL, Wilkinson IB. Circulation. 2011 Feb 8;123(5):515-23.
Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction. Wallace SM, Mäki-Petäjä KM, Cheriyan J, Davidson EH, Cherry L, McEniery CM, Sattar N, Wilkinson IB, Kharbanda RK. Br J Clin Pharmacol. 2010 Dec;70(6):799-806.
The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans. Cheriyan J, Burton TJ, Bradley TJ, Wallace SM, Mäki-Petäjä KM, Mackenzie IS, McEniery CM, Brown J, Wilkinson IB. Br J Clin Pharmacol. 2009 Oct;68(4):518-23.
The accuracy of central SBP determined from the second systolic peak of the peripheral pressure waveform. Hickson SS, Butlin M, Mir FA, Graggaber J, Cheriyan J, Khan F, Grace AA, Yasmin, Cockcroft JR, Wilkinson IB, McEniery CM; Anglo-Cardiff Collaboration Trial Investigators. J Hypertens. 2009 Sep;27(9):1784-8.